Compare ALSN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALSN | LEGN |
|---|---|---|
| Founded | 1915 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 5.9B |
| IPO Year | 2012 | 2020 |
| Metric | ALSN | LEGN |
|---|---|---|
| Price | $98.31 | $21.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $95.86 | $69.58 |
| AVG Volume (30 Days) | 988.2K | ★ 2.4M |
| Earning Date | 02-10-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.15 | N/A |
| Revenue | ★ $3,069,000,000.00 | $909,045,000.00 |
| Revenue This Year | N/A | $68.52 |
| Revenue Next Year | $0.23 | $48.63 |
| P/E Ratio | $12.01 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $76.01 | $21.19 |
| 52 Week High | $121.81 | $45.30 |
| Indicator | ALSN | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 31.91 |
| Support Level | $97.04 | $21.19 |
| Resistance Level | $101.09 | $23.24 |
| Average True Range (ATR) | 1.74 | 0.67 |
| MACD | -0.50 | 0.18 |
| Stochastic Oscillator | 20.84 | 27.14 |
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.